The American Heart Association’s (AHA) 2023 Scientific Session was held in Philadelphia from November 11-13. This is one of the premier scientific meetings of the year with over 10,000 clinicians and researchers in attendance. Sessions focused on the latest research and insights to improve cardiovascular … Read More →
On October 3, after the conclusion of another successful Global Summit, the Family Heart Foundation hosted a congressional briefing at the Rayburn House Office building on Capitol Hill entitled, “Opportunities to Reduce the Rising Tide of Heart Disease Through Better LDL-Cholesterol Management.” … Read More →
September is National Cholesterol Education Month, and that makes it the perfect time to shine a light on cholesterol management in America. Family Heart Foundation research shows that 70% of Americans at high-risk for cardiovascular disease never get their LDL (“bad”) cholesterol to recommended … Read More →
A Response to the US Preventive Service Task Force
On January 24, 2023, the US Preventive Services Task Force (USPSTF) released their draft recommendation based on evidence of the benefits and harms of screening for lipid disorders, including familial hypercholesterolemia (FH), in children and … Read More →
New Data and Findings
The American Heart Association’s (AHA) 2022 Scientific Session was held in Chicago from November 4-6. This is one of the premier scientific meetings of the year with over 10,000 clinicians and researchers in attendance, Sessions focused on the latest research and insights to … Read More →
Today the FDA announced the approval of inclisiran (Leqvio) as a treatment for adults with heterozygous familial hypercholesterolemia (HeFH) or clinical atherosclerotic cardiovascular disease (ASCVD) who require additional low-density lipoprotein cholesterol (LDL-C) lowering. Inclisiran is an injection … Read More →
Reducing the Burden of Familial Hypercholesterolemia
Healthcare systems around the world have failed to rescue individuals born with Familial Hypercholesterolemia (FH), even though we have had life-saving therapies for the last 34 years. Without the societal commitment to screen, diagnose, and manage … Read More →
The Food and Drug Administration (FDA) approved today a new drug to treat adult and pediatric patients aged 12 years and older with Homozygous Familial Hypercholesterolemia (HoFH), the rare and most severe form of FH.This is welcome news, as individuals with HoFH usually are not able to adequately … Read More →
The Institute for Clinical and Economic Review (ICER) – an organization that produces reports that analyze the cost effectiveness of drugs and other medical services – has highlighted the improved cost-effectiveness of high cholesterol treatments inclisiran and bempedoic acid in patients who have … Read More →
the Family Heart Foundation started 2021 off with an impactful Listening Session with the Food and Drug Administration (FDA) Center for Drug Evaluation and Research Division of Diabetes, Lipid Disorders, and Obesity (DDLO) on Homozygous Familial Hypercholesterolemia (HoFH) on January 4. Kate Robinson … Read More →
